Expert Insights on Japanese Pharmaceutical Industry Trends
Despite being the second largest pharmaceutical market in 2008, Japan has experienced a lower growth rate than other major pharmaceutical markets, with the government’s imposed price control serving as a key contributing factor.
Get expert insights on:
- M&A activity and overall consolidation in the Japanese pharmaceutical market
- Market entry of generic manufacturers
- Pricing and reimbursement in Japan
Gerson Lehrman Group Council Members are available to discuss Japanese Pharmaceutical Industry Trends via phone consultations, live meetings, surveys, and other custom GLG products and services.
Find, engage, and manageSM experts today through the GLG platform
Featured Council Members
GLG Council Members are leading experts including academics, scientists, and industry specialists
-
Nitin Naik
Vice PresidentFROST & SULLIVAN, INC
-
Peter Gensheimer
DirectorSAVILLS JAPAN K.K.
-
Daniel Lintz
President & Chief Executive OfficerSafe Harbour Japan K.K.
-
Peter Culpepper, CPA, MBA
Chief Financial OfficerProvectus Pharmaceuticals, Inc.
-
William Shannon, PhD
Founder and PresidentBioRankings, LLC
Study Groups
Study groups are populations of experts knowledgeable on specific sub-topics within a broader industry
| Study Group Name | No. Members |
|---|---|
| Immunologists (Asia) | 26 |
| Internal Medicine Physicians (Japan) | 108 |
| Ophthalmologists (Japan) | 10 |
| Obstetricians/Gynecologists (Japan) | 11 |
| Internal Medicine Physicians (Asia) | 13 |
Recent Live Meetings
Interactive roundtables, private visits, and small scale seminars are types of GLG Live Meetings
-
May 22, 2009 | Webcast
GLG Webcast: Consolidation Trends - China Pharma on May 22, 2009 at 7:30AM ET -
December 2, 2009 | San Francisco
Seminar: Global Steel Update – Outlook for 2010 (San Francisco)
Recent News Analyses
News analyses are expert commentaries on current events, written by Council Members who are available for follow up consultations
-
November 19, 2009
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, STANFORD UNIVERSITY
Leo Pharma completes merger pact with Peplin | www.pharmabiz.com
The recent merger of Peplin with Leo pharma is of some significance and will benefit both companies. It would have been difficult for Peplin to fully develop and market their flagship product alone.
-
Pharma Outsourcing: Where Will it End?
November 3, 2009
Quintiles inks pharma deals | www.outsourcing-pharma.com
A major supplier of clinical development services has just been awarded all of Astra Zeneca's clinical pharmacology work. Such work was traditionally performed internally but is now one of many stages of development being outsourced. This follows similar trends in research, where pharma companies are...
-
Japan Consumer Finance Regulation Faces Final Hurdle
November 1, 2009
Daniel Lintz, President & Chief Executive Officer, Safe Harbour Japan K.K.
Govt May Backtrack On Tighter Moneylender Regulations | www.nni.nikkei.co.jp
A committee of policy makers assigned to the Financial Services Agency, Consumer Affairs Ministry and Ministry of Justice will convene this month to assess the impact of Revisions to the Money Lending Business Law on the consumer credit industry in Japan. The committee will either recommendto...
-
Japan Post President to Resign as DPJ Rolls Back Privatization Reforms
October 19, 2009
Daniel Lintz, President & Chief Executive Officer, Safe Harbour Japan K.K.
Kamei: Japan Post boss on notice | search.japantimes.co.jp
The Yomiuri Shimbun reports the imminent resignation of Japan Post Holdings President Yoshifumi Nishikawa following his meeting yesterday with State Minister for Postal Services and Financial Affairs Hon. Shizuka Kamei.
-
GSK's cervical cancer vaccine Cervarix gains approval in Japan
October 19, 2009
GSK's cervical cancer vaccine Cervarix gains approval in Japan | www.pharmabiz.com
GlaxoSmithKline (GSK) gained approval for Cervarix in Japan, which becomes the first cervical cancer vaccine to be approved by the Japanese Ministry of Health, Labour and Welfare (MHLW). This approval marks a significant milestone for GSK, as Cervarix will be the first to be launched by the company's...